Clinical Profile and Prognosis of Patients with Left-Sided Infective Endocarditis with Surgical Indication Who Are Not Operated
Abstract
:1. Introduction
2. Methods
2.1. Population
2.2. The Decision-Making Process
2.3. Reasons for Rejection
- Very high surgical risk to the patient and decided by the ET, based on the risk scores available, particularly EUROSCORE II, STS score, RISK-E [13] and the ENDOVAL risk score since 2020. Other conditions which may impact the general prognosis of the patient not considered in the scores (cancer, severe liver disease and/or hemodynamic instability) were also taken into account. Very high surgical risk could also be related to an important structural destruction of the valvular and surrounding tissues not amenable to a surgical repair.
- Severe neurological conditions, defined as a previous stroke or other neurological diseases with a negative impact on the patient’s daily life, and that shorten his/her life expectancy, or a current hemorrhagic stroke except that which is secondary to a mycotic aneurysm with no clinical sequalae. The rejection for surgery due to this condition was always discussed with a neurologist.
- Other reasons: Surgical indications accepted in the guidelines have a B or C level of evidence. Thus, some of those indications were not strictly followed. These conditions were not considered an indication for surgery per se: mild heart failure controlled with low doses of diuretics, persistent infection when an alternative antibiotic regimen based on the antibiogram was possible (a specialist in infectious diseases was always consulted in this case) and/or big valvular vegetations without a previous stroke.
2.4. Statistics
3. Results
3.1. Cohort Identification
3.2. Demographic, Clinical, Microbiological, Echocardiographic Characteristics and Outcome of Patients with Surgical Indication Not Operated On
3.3. Causes of Rejection for Surgery
3.4. Type of Surgical Indication
3.5. Predictors of Mortality in Patients with Surgical Indication Not Operated On
3.6. Role of Percutaneous Treatment in Patients Not Operated on Who Have an Indication for Surgery
4. Discussion
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Olmos, C.; Vilacosta, I.; Fernández-Pérez, C.; Bernal, J.L.; Ferrera, C.; García-Arribas, D.; Pérez-García, C.N.; San Román, J.A.; Maroto, L.; Macaya, C.; et al. The evolving nature of infective endocarditis in Spain. J. Am. Coll. Cardiol. 2017, 70, 2795–2804. [Google Scholar] [CrossRef]
- Murdoch, D.R.; Corey, G.R.; Hoen, B.; Miró, J.M.; Fowler, V.G.; Bayer, A.S.; Karchmer, A.W.; Olaison, L.; Pappas, P.A.; Moreillon, P.; et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: The International Collaboration on Endocarditis–Prospective Cohort Study. Arch. Intern. Med. 2009, 169, 463–473. [Google Scholar] [CrossRef]
- Hill, E.E.; Herijgers, P.; Claus, P.; Vanderschueren, S.; Herregods, M.; Peetermans, W.E. Infective endocarditis: Changing epidemiology and predictors of 6-month mortality: A prospective cohort study. Eur. Heart J. 2007, 28, 196–203. [Google Scholar] [CrossRef]
- Chu, V.H.; Park, L.P.; Athan, E.; Delahaye, F.; Freiberger, T.; Lamas, C.; Miro, J.M.; Mudrick, D.W.; Strahilevitz, J.; Tribouilloy, C.; et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: A prospective study from the International Collaboration on Endocarditis. Circulation 2015, 131, 131–140. [Google Scholar] [CrossRef]
- Lung, B.; Doco-Lecompte, T.; Chocron, S.; Strady, C.; Delahaye, F.; Le Moing, V.; Poyart, C.; Alla, F.; Cambau, E.; Tattevin, P.; et al. Cardiac surgery during the acute phase of infective endocarditis: Discrepancies between European Society of Cardiology guidelines and practices. Eur. Heart J. 2016, 37, 840–848. [Google Scholar] [CrossRef]
- Habib, G.; Lancellotti, P.; Antunes, M.J.; Bongiorni, M.G.; Casalta, J.P.; Del Zotti, F.; Dulgheru, R.; El Khoury, G.; Erba, P.A.; Lung, B.; et al. 2015 ESC guidelines for the management of infective endocarditis: The task force for the management of infective endocarditis of the European society of cardiology (ESC). Endorsed by: European association for cardio-thoracic surgery (EACTS), the European association of nuclear medicine (EANM). Eur. Heart J. 2015, 36, 3075–3128. [Google Scholar] [CrossRef]
- Otto, C.M.; Nishimura, R.A.; Bonow, R.O.; Carabello, B.A.; Erwin III, J.P.; Gentile, F.; Jneid, H.; Krieger, E.V.; Marck, M.; McLeod, C.; et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021, 143, 35–71. [Google Scholar] [CrossRef]
- Habib, G.; Hoen, B.; Tornos, P.; Thuny, F.; Prendergast, B.; Vilacosta, I.; Moreillon, P.; Antunes, M.J.; Thilen, U.; Lekakis, J.; et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur. Heart J. 2009, 30, 2369–2413. [Google Scholar] [CrossRef] [PubMed]
- Horstkotte, D.; Follath, F.; Gutschik, E.; Lengyel, M.; Oto, A.; Pavie, A.; Soler-soler, J.; Thiene, G.; Von Graevenitz, A.; Priori, S.G.; et al. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary The Task Force on Infective Endocarditis of the European Society of Cardiology. Eur. Heart J. 2004, 25, 267–276. [Google Scholar] [CrossRef] [PubMed]
- Carino, D.; Fernández-Cisneros, A.; Hernández-Meneses, M.; Sandoval, E.; Llopis, J.; Falces, C.; Miró, J.M.; Quintana, E. The fate of active left-side infective endocarditis with operative indication in absence of valve surgery. J. Card Surg. 2020, 35, 3034–3040. [Google Scholar] [CrossRef] [PubMed]
- Camazón, N.V.; Cediel, G.; Aragón, R.N.; Mateu, L.; Llibre, C.; Sopena, N.; Gual, F.; Ferrer, E.; Quesada, M.D.; Berastegui, E.; et al. Mortalidad a corto y largo plazo de pacientes con indicación quirúrgica no intervenidos en el curso de la endocarditis infecciosa izquierda. Rev. Esp. Cardiol. 2020, 73, 734–740. [Google Scholar] [CrossRef]
- Van Hemelrijck, M.; Sromicki, J.; Greutmann, M.; Ledergerber, B.; Epprecht, J.; Padrutt, M.; Vogt, P.R.; Carrel, T.P.; Dzemali, O.; Mestres, C.A.; et al. Dismal prognosis of patients with operative indication without surgical intervention in active left-sided infective endocarditis. Front. Cardiovasc. Med. 2023, 10, 1223878. [Google Scholar] [CrossRef]
- Olmos, C.; Vilacosta, I.; Habib, G.; Maroto, L.; Fernández, C.; López, J.; Sarriá, C.; Salaun, E.; Di Stefano, S.; Carnero, M.; et al. Risk score for cardiac surgery in active left-sided infective endocarditis. Heart 2017, 103, 1435–1442. [Google Scholar] [CrossRef]
- Bansal, A.; Cremer, P.C.; Jaber, W.A.; Rampersad, P.; Menon, V. Sex differences in the utilization and outcomes of cardiac valve replacement surgery for infective endocarditis: Insights from the National Inpatient Sample. J. Am. Heart Assoc. 2021, 10, e020095. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Martínez, A.; Calderón-Parra, J.; Miró, J.M.; Muñoz, P.; Rodríguez-Abella, H.; Valerio, M.; De Alarcón, A.; Luque, R.; Ambrosioni, J.; Fariñas, M.C.; et al. Effect of the type of surgical indication on mortality in patients with infective endocarditis who are rejected for surgical intervention. Int. J. Cardiol. 2019, 282, 24–30. [Google Scholar] [CrossRef] [PubMed]
- Fernández-Hidalgo, N.; Almirante, B.; Tornos, P.; González-Alujas, M.T.; Planes, A.M.; Galiñanes, M.; Pahissa, A. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. Clin. Microbiol. Infect. 2012, 18, E522–E530. [Google Scholar] [CrossRef]
- Delgado, V.; Marsan, N.A.; de Waha, S.; Bonaros, N.; Brida, M.; Burri, H.; Caselli, S.; Doenst, T.; Ederhy, S.; Erba, P.A.; et al. 2023 ESC Guidelines for the management of endocarditis. Eur. Heart J. 2023, 44, 3948–4042. [Google Scholar] [CrossRef]
- Cabezón, G.; López, J.; Vilacosta, I.; Saez, C.; Garcia-Granja, P.E.; Olmos, C.; Jerónimo, A.; Gutiérrez, A.; Pulido, P.; de Miguel, M.; et al. Reassessment of vegetation size as a sole indication for surgery in left-sided infective endocarditis. J. Am. Soc. Echocardiogr. 2022, 35, 570–575. [Google Scholar] [CrossRef] [PubMed]
- Martin, B.; Leon, M.B.; Smith, C.R.; Mack, M.; Moses, J.W.; Svensson, L.G.; Turzcu, E.M.; Webb, J.G.; Fontana, G.P.; Makkar, R.R.; et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 2010, 363, 1597–1607. [Google Scholar] [CrossRef]
- Arnold, S.V.; Reynolds, M.R.; Wang, K.; Magnuson, E.A.; Baron, S.J.; Chinnakondepalli, K.M.; Reardon, M.J.; Tadros, P.N.; Zorn, G.L.; Maini, B.; et al. Health status after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis at increased surgical risk: Results from the CoreValve US Pivotal Trial. JACC Cardiovasc. Interv. 2015, 8, 1207–1217. [Google Scholar] [CrossRef]
- Santos-Martínez, S.; Alkhodair, A.; Nombela-Franco, L.; Saia, F.; Muñoz-García, A.J.; Gutiérrez, E.; Regueiro, A.; Jimenez-Diaz, V.A.; Rivero, F.; Romaguera, R.; et al. Transcatheter aortic valve replacement for residual lesion of the aortic valve following “healed” infective endocarditis. JACC Cardiovasc. Interv. 2020, 13, 1983–1996. [Google Scholar] [CrossRef] [PubMed]
- Rasmussen, R.V.; Bruun, L.E.; Lund, J.; Larsen, C.T.; Hassager, C.; Bruun, N.E. The impact of cardiac surgery in native valve infective endocarditis: Can euroSCORE guide patient selection? Int. J. Cardiol. 2011, 149, 304–309. [Google Scholar] [CrossRef] [PubMed]
VARIABLE | GROUP A IE with Surgical Indication Not Operated (n = 303) | GROUP B IE Operated (n = 595) | P |
---|---|---|---|
Epidemiological and clinical characteristics: | |||
Mean age (years) | 73.2 ± 11.7 | 64.4 ± 13.8 | <0.001 |
<70 years | 88 (29.0) | 241 (57.3) | <0.001 |
Female | 124 (40.9) | 182 (30.6) | 0.002 |
Referred | 120 (39.6) | 348 (58.5) | <0.001 |
Nosocomial | 86 (28.5) | 134 (22.5) | 0.050 |
Possible port of entry: | |||
Dental manipulation | 8 (2.6) | 43 (7.2) | 0.005 |
Gastrointestinal manipulation | 15 (5.0) | 28 (4.7) | 0.863 |
Genitourinary manipulation | 16 (5.3) | 21 (3.5) | 0.208 |
Intravascular catheter | 53 (17.5) | 68 (11.4) | 0.011 |
Predisposing conditions: | |||
Alcoholism | 15 (5.0) | 50 (8.4) | 0.060 |
Diabetes | 99 (32.8) | 150 (25.2) | 0.017 |
History of cancer | 48 (15.8) | 62 (10.4) | 0.018 |
Immunosuppression | 28 (9.2) | 43 (7.2) | 0.284 |
Cancer | 48 (15.9) | 62 (10.4) | 0.018 |
Chronic renal failure | 73 (24.1) | 69 (11.6) | <0.001 |
Anemia | 93 (30.7) | 136 (23) | 0.010 |
Previous known heart disease | 216 (73.5) | 383 (65.9) | 0.023 |
Mode of presentation: | |||
Heart failure at admission | 115 (38.9) | 268 (45.0) | 0.079 |
Renal insufficiency at admission | 109 (36.8) | 145 (24.4) | <0.001 |
Septic shock at admission | 40 (13.5) | 47 (7.9) | 0.008 |
Positive blood cultures at admission | 260 (88.7) | 453 (81.0) | 0.004 |
Microbiological profile: | |||
S. gallolyticus | 11 (3.6) | 40 (6.7) | 0.058 |
Viridans-group Streptococci | 33 (10.9) | 98 (16.5) | 0.025 |
Enterococcus spp | 59 (19.5) | 80 (13.5) | 0.019 |
Other Streptococci | 18 (5.9) | 39 (6.6) | 0.717 |
Staphylococcus aureus | 87 (28.7) | 101 (17.0) | <0.001 |
Methicillin resistant | 18/87 (20.7) | 20/101 (19.8) | 0.880 |
Coagulase negative Staphylococci | 53 (17.5) | 114 (19.2) | 0.536 |
Methicillin resistant | 35/53 (66.0) | 72/114 (63.2) | 0.718 |
Gram negative bacilli | 16 (5.3) | 19 (3.2) | 0.128 |
Fungi | 3 (1.0) | 19 (3.2) | 0.043 |
HACEK | 1 (0.3) | 3 (0.5) | 0.999 |
Anaerobes | 2 (0.7) | 16 (2.7) | 0.040 |
Polymicrobial | 12 (4.0) | 30 (5.0) | 0.465 |
Others | 4 (1.3) | 20 (3.4) | 0.072 |
Persistent positive blood cultures | 74 (38.9) | 119 (30.2) | 0.035 |
Negative blood cultures | 23 (7.6) | 61 (10.3) | 0.193 |
Persistent infection | 105 (37.0) | 169 (29.5) | 0.027 |
Echocardiographic characteristics: | |||
Vegetation | 280 (92.4) | 514 (86.5) | 0.008 |
Periannular complication | 82 (27.1) | 244 (41.0) | <0.001 |
Valvular stenosis | 86 (28.4) | 139 (23.4) | 0.101 |
Valvular rupture | 17 (5.6) | 57 (9.6) | 0.041 |
Moderate-severe regurgitation | 181 (59.7) | 445 (74.8) | <0.001 |
Aortic valve | 76 (25.1) | 226 (38.0) | <0.001 |
Mitral valve | 130 (42.9) | 214 (36.0) | 0.045 |
Prosthetic valve EI | 134 (44.2) | 241 (40.5) | 0.285 |
Native valve IE | 188 (62.0) | 381 (64.0) | 0.559 |
Moderate to severe pulmonary arterial hypertension (PAH) | 195 (64.4) | 305 (51.2) | 0.094 |
Surgical risk and prognosis: | |||
Logistic Euroscore | 39.1 [19.6–56.2] | 21.9 [8.6–44.5] | <0.001 |
Euroscore II | 9.4 [4.6–20.2] | 6.6 [2.2–14.8] | 0.015 |
Hospital mortality | 140 (46.2) | 144 (24.2) | <0.001 |
One year mortality | 173 (57.1) | 164 (27.6) | <0.001 |
Laboratory *: | |||
White blood cell (WBC) count | 11,000 [7815–15,655] | 10,500 [7695–14,045] | 0.314 |
Erythrocyte sedimentation rate (ESR) | 65 [40–94] | 55 [36–80.5] | 0.018 |
C-reactive protein (CRP) | 16.7 [8.3–56.6] | 14.8 [6.2–53.7] | 0.206 |
Procalcitonin (PCT) | 1.1 [0.2–27.0] | 0.4 [0.1–7.1] | 0.016 |
CAUSE OF REJECTION | ||||
---|---|---|---|---|
High Risk (n = 173) | Neurological Condition (n = 53) | ET Decision (n = 77) | p | |
In-hospital mortality | 95 (55%) | 40 (76%) | 5 (7%) | <0.001 |
One-year mortality | 116 (67%) | 44 (83%) | 13 (17%) | <0.001 |
HOSPITAL MORTALITY | ||||
---|---|---|---|---|
UNIVARIATE | MULTIVARIATE | |||
OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
Age | 1.02 (1.01–1.04) | 0.023 | ||
Renal failure | 1.81 (1.06–3.09) | 0.029 | ||
Heart failure | 2.67 (1.65–4.32) | <0.001 | 2.26 (1.29–3.96) | 0.005 |
Septic shock | 2.54 (1.19–5.45) | 0.017 | ||
S. viridans | 0.14 (0.05–0.40) | <0.001 | 0.18 (0.05–0.66) | 0.009 |
S. aureus | 4.39 (2.55–7.54) | <0.001 | 3.17 (1.72–5.86) | <0.001 |
Persistent infection | 5.89 (3.45–10.05) | <0.001 | 5.07 (2.85–9.03) | <0.001 |
Periannular complications | 1.85 (1.11–3.09) | 0.019 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
de Miguel, M.; López, J.; Vilacosta, I.; Olmos, C.; Sáez, C.; Cabezón, G.; Zulet, P.; Jerónimo, A.; Gómez, D.; Pulido, P.; et al. Clinical Profile and Prognosis of Patients with Left-Sided Infective Endocarditis with Surgical Indication Who Are Not Operated. Microorganisms 2024, 12, 607. https://doi.org/10.3390/microorganisms12030607
de Miguel M, López J, Vilacosta I, Olmos C, Sáez C, Cabezón G, Zulet P, Jerónimo A, Gómez D, Pulido P, et al. Clinical Profile and Prognosis of Patients with Left-Sided Infective Endocarditis with Surgical Indication Who Are Not Operated. Microorganisms. 2024; 12(3):607. https://doi.org/10.3390/microorganisms12030607
Chicago/Turabian Stylede Miguel, María, Javier López, Isidre Vilacosta, Carmen Olmos, Carmen Sáez, Gonzalo Cabezón, Pablo Zulet, Adrián Jerónimo, Daniel Gómez, Paloma Pulido, and et al. 2024. "Clinical Profile and Prognosis of Patients with Left-Sided Infective Endocarditis with Surgical Indication Who Are Not Operated" Microorganisms 12, no. 3: 607. https://doi.org/10.3390/microorganisms12030607
APA Stylede Miguel, M., López, J., Vilacosta, I., Olmos, C., Sáez, C., Cabezón, G., Zulet, P., Jerónimo, A., Gómez, D., Pulido, P., Lozano, A., Oña, A., Gómez-Salvador, I., & San Román, J. A. (2024). Clinical Profile and Prognosis of Patients with Left-Sided Infective Endocarditis with Surgical Indication Who Are Not Operated. Microorganisms, 12(3), 607. https://doi.org/10.3390/microorganisms12030607